Benzinga | Jun 22, 2021 06:45AM EDT

Qiagen Launches CRISPR-Specific Products For Gene-Editing Experiments

* Qiagen NV (NYSE:QGEN) has launched dedicated solutions specific to CRISPR technology used for editing genomes and modifying gene function.

* QiaPrep&Amp CRISPR Kit and Q-Primer Solutions expand Qiagen portfolio for CRISPR applications.

* The solutions allow researchers to analyze edited genetic material with speed and efficiency to determine how their interventions have changed the function of the DNA sequence in question.

* The new products add to the range of Qiagen products that could also be used for CRISPR research, such as the QIAGEN EndoFree Plasmid Kits and Plasmid Plus Kits.

* Price Action: QGEN shares closed at $47.26 on Monday.